Develops sustained-release eye implants for cataract surgeons treating patients with glaucoma or ocular hypertension.
10-K for FY2025, filed Mar 26, 2026
No revenue reported yet.
10-K for FY2025, filed Mar 26, 2026
10-Q for Q3 FY2026, filed Nov 12, 2026
−$24.3MView ↗
8-K, filed Oct 1, 2026
The aggregate consideration paid by the Company at the Closing for the Shares was based on a purchase price of $13,000,000, subject to…View ↗
Competes with Alcon, Allergan, AbbVie, Bausch & Lomb, Glaukos, Johnson & Johnson, Astellas, Genentech, Roche, and Regeneron
10-K for FY2025, filed Mar 26, 2026Our lead product candidate, the BIM-IOL System, is designed to treat OAG and OHT, placing us in direct competition with a range of…View ↗
Loading...